HDAC9 and non-small cell lung carcinoma: Moreover, in non-small cell lung cancer, the combined treatment of HDAC inhibitors and AZA has shown a significant anti-tumor response by inhibiting myc-driven cell proliferation and amplifying immune signals (Topper et al., 2017).